Assessing response to osteoporosis therapy

Osteoporosis International

Volumn 19, Issue 10, 2008, Pages 1363-1368

  Lewiecki, E M ^a   Watts, N B ^b  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Bone mineral density; Bone turnover marker; Dual energy X ray absorptiometry; Fracture; Nonresponder; Osteoporosis; Responder; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; AROMATASE INHIBITOR; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GLUCOCORTICOID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; VITAMIN D;

BONE ATROPHY; BONE DENSITOMETRY; BONE MASS; BONE STRENGTH; BONE TURNOVER; CALCIUM INTAKE; CLINICAL PRACTICE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DRUG TREATMENT FAILURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FALLING; FRAGILITY FRACTURE; HEALTH CARE COST; HORMONAL THERAPY; HUMAN; LABORATORY TEST; MALABSORPTION; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STATISTICAL SIGNIFICANCE; THYROID DISEASE; TREATMENT OUTCOME; VITAMIN INTAKE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DRUG MONITORING; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; PRESCRIPTION DRUGS; TREATMENT OUTCOME;

EID: 51249092593     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0661-8     Document Type: Review

References (29)

1. Kanis JA, on behalf of the World Health Organization Scientific Group (2007) (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK: Printed by the University of Sheffield.
2. JC Lotz EJ Cheal WC Hayes 1991 Fracture prediction for the proximal femur using finite element models: Part I-Linear analysis J Biomechan Eng 113 353 360
3. D Marshall O Johnell H Wedel 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures BMJ 312 1254 1259
4. JA Kanis the WHO Study Group 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis Osteoporos Int 4 368 381
5. A Cranney P Tugwell G Wells G Guyatt 2002 Systematic reviews of randomized trials in osteoporosis: Introduction and methodology Endocr Rev 23 497 507
6. RD Wasnich PD Miller 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density J Clin Endocrinol Metab 85 231 236
7. R Mazess CH Chesnut III M McClung H Genant 1992 Enhanced precision with dual-energy X-ray absorptiometry Calcif Tissue Int 51 14 17
8. N Binkley JP Bilezikian DL Kendler ES Leib EM Lewiecki SM Petak 2006 Official Positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference J Clin Densitom 9 4 14
9. C MacLean S Newberry M Maglione M McMahon V Ranganath M Suttorp W Mojica M Timmer A Alexander M McNamara SB Desai A Zhou S Chen J Carter C Tringale D Valentine B Johnsen J Grossman 2008 Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis Ann Intern Med 148 197 213
10. US Department of Health and Human Services (2004) Bone Health and Osteoporosis: A Report of the Surgeon General. US Department of Health and Human Services, Office of the Surgeon General.
11. JA Cramer DT Gold SL Silverman EM Lewiecki 2007 A systematic review of persistence and compliance with bisphosphonates for osteoporosis Osteoporos Int 18 1023 1031
12. Diez-Perez A, Gonzalez-Macias J (2008) Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int DOI 10.1007/s00198-008-0659-2
13. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822
14. P Garnero E Hausherr M-C Chapuy C Marcelli H Grandjean C Muller C Cormier G Breart PJ Meunier PD Delmas 1996 Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study J Bone Miner Res 11 1531 1538
15. R Dowd RR Recker RP Heaney 2000 Study subjects and ordinary patients Osteoporos Int 11 533 536
16. CH Chesnut III S Silverman K Andriano H Genant A Gimona S Harris D Kiel M LeBoff M Maricic P Miller C Moniz M Peacock P Richardson N Watts D Baylink PROOF Study Group 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study Am J Med 109 267 276
17. Watts NB, Miller PMR, Chen P, Arsenault J, Krohn K (2008) Vertebral fracture risk is reduced for women who lose femoral neck bone mineral density during teriparatide therapy [abstract]. J Clin Densitom 11:In press
18. RD Chapurlat L Palermo P Ramsay SR Cummings The Fracture Intervention Trial 2005 Risk of fracture among women who lose bone density during treatment with alendronate Osteoporos Int 16 842 848
19. S Baim N Binkley JP Bilezikian DL Kendler DB Hans EM Lewiecki S Silverman 2008 Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 position development conference J Clin Densitom 11 75 91
20. EM Lewiecki LA Rudolph 2002 How common is loss of bone mineral density in elderly clinical practice patients receiving oral bisphosphonate therapy for osteoporosis? J Bone Miner Res 17 Suppl 2 S367
21. DC Bauer DM Black P Garnero M Hochberg S Ott J Orloff DE Thompson SK Ewing PD Delmas 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial J Bone Miner Res 19 1250 1258
22. EM Lewiecki 2003 Nonresponders to osteoporosis therapy J Clin Densitom 6 307 314
23. A Del Puente A Scognamiglio E Itto G Ferrara P Oriente 2000 Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis J Rheumatol 27 1980 1983
24. S Adami G Isaia G Luisetto S Minisola L Sinigaglia R Gentilella D Agnusdei N Iori R Nuti 2006 Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study J Bone Miner Res 21 1565 1570
25. GA Heckman A Papaioannou RJ Sebaldt G Ioannidis A Petrie C Goldsmith JD Adachi 2002 Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates BMC Musculoskelet Disord 3 6
26. AM Sawka JD Adachi G Ioannidis WP Olszynski JP Brown DA Hanley T Murray R Josse RJ Sebaldt A Petrie A Tenenhouse A Papaioannou CH Goldsmith 2003 What predicts early fracture or bone loss on bisphosphonate therapy? J Clin Densitom 6 315 322
27. F Jakob F Marin E Martin-Mola D Torgerson P Fardellone S Adami NC Thalassinos D Sykes J Melo-Gomes C Chinn T Nicholson C Cooper 2006 Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO) QJM 99 531 543
28. B Obermayer-Pietsch T Nickelsen F Marin C Barker P Hadji J Farrerons M Audran S Boonen A Anastasilakis E McCloskey 2006 Response of BMD to 24 months of teriparatide (rhPTH 1-34) in patients with and without prior antiresorptive treatment: final results from the EUROFORS study J Bone Miner Res 21 Suppl 1 S43
29. NICE (National Institute for Clinical Excellence) (2004) Final appraisal determination- secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE: